At a recent meeting of the Pharmaceutical Onology Initiative’s (POI) HTA group, OHE’s Nancy Devlin provided an overview of the EuroQol Group’s scientific research agenda for the coming year and plans for the EQ-5D-5L approach to measuring patient-reported outcomes of care. Health technology assessment affects patients’ access to oncology medicines. The EQ-5D is the principal instrument for measuring health related quality of life for HTA purposes, making planned developments in EQ-5D instruments and value sets important in decision making. Nancy’s presentation appears below.
OHE currently is working under a research grant from the Policy Research Programme (PRP) of the UK’s National Institute for Health Research (NIHR) to produce an EQ-5D-5L Value Set for England. For additional information on the focus and approach of this reseach, see our earlier blog post. For information on other recent OHE activities in this areas, see our December blog post.
For additional information, please contact Nancy Devlin at OHE.
 The POI is a group of pharmaceutical companies, all members of the Association of the British Pharmaceutical Industry, that work with and support the NHS in improving the delivery of cancer services. For more information, see http://www.abpi.org.uk/our-work/value-access/groups/Pages/poi.aspx